Shukra Pharmaceuticals Issues Corrigendum for Planned Rebranding

Revenue from Pharmaceuticals: Rs 7,483.73 Lakhs; Investment in New Medtech Business: Rs 5,058.31 Lakhs.

Reader Takeaway: Procedural update for a name change; no impact on e-voting deadlines or core business transition strategy.

What just happened

Shukra Pharmaceuticals Limited has issued a corrigendum to its August 22, 2026, Postal Ballot Notice. The company is seeking shareholder approval to alter its Main Object Clause and rename itself to "Shukra Medtech Limited." The update involves replacing the Independent Auditor's Certificate with a revised version dated September 16, 2026, to meet BSE observations under SEBI regulations.

Why this matters

The revised certificate clarifies the firm's financial position, confirming that while its revenue currently stems entirely from pharmaceuticals, over 51% of its investments have already been allocated toward the new Medical Technology business segment. This transparency is a regulatory requirement for the company to proceed with its official shift in business focus.

Shareholder E-Voting Instructions

The e-voting window remains open until September 26, 2026, at 5:00 P.M. IST. Shareholders who have already voted may choose to cast a new vote if they wish; otherwise, previously cast votes remain valid and will be counted. This corrigendum does not alter the voting timeline or the core resolutions put forward to shareholders.

Context Metrics

As of the period ending June 30, 2026, the company reported a total investment allocation of Rs 9,910.49 Lakhs, with 51.04% directed toward the upcoming Medtech activity and 48.96% in its traditional pharmaceutical business.